Keyword: Sanofi

If you’ve been paying attention this week, you’ve seen nearly every Big Pharma has been sweeping out dead R&D projects: Sanofi is no different.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.

Pfizer’s ED drug Viagra facilitates the release of stem cells from the bone marrow into the bloodstream, which could ease collection.

John Cox, who led Bioverativ through its $11.6 billion Sanofi buyout, is helming Torque, which is working on "deep-primed" T-cell therapies for cancer.

Pfizer’s JAK inhibitor cleared patients’ skin and improved atopic dermatitis symptoms in a second phase 3 study.

The Medicines Company reported that its PCSK9 drug, inclisiran, cut "bad" LDL cholesterol in patients with plaque buildup in their arteries.

The IPO window is still wide open for biotech, and French Big Pharma-partnered Innate is looking to jump right on through.

Abbott and Sanofi are partnering up to develop tools that connect their respective blood sugar tracking and insulin delivery technologies.

The study tested a 20 mg dose of ponesimod against a 14 mg dose of Aubagio in adults with relapsing multiple sclerosis over a period of two years.